These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

279 related items for PubMed ID: 23617484

  • 1. Microsimulation model predicts survival benefit of radiofrequency ablation and stereotactic body radiotherapy versus radiotherapy for treating inoperable stage I non-small cell lung cancer.
    Tramontano AC, Cipriano LE, Kong CY, Shepard JA, Lanuti M, Gazelle GS, McMahon PM.
    AJR Am J Roentgenol; 2013 May; 200(5):1020-7. PubMed ID: 23617484
    [Abstract] [Full Text] [Related]

  • 2. Comparison of the Effectiveness of Radiofrequency Ablation With Stereotactic Body Radiation Therapy in Inoperable Stage I Non-Small Cell Lung Cancer: A Systemic Review and Pooled Analysis.
    Bi N, Shedden K, Zheng X, Kong FS.
    Int J Radiat Oncol Biol Phys; 2016 Aug 01; 95(5):1378-1390. PubMed ID: 27479723
    [Abstract] [Full Text] [Related]

  • 3. Is radiofrequency ablation more effective than stereotactic ablative radiotherapy in patients with early stage medically inoperable non-small cell lung cancer?
    Bilal H, Mahmood S, Rajashanker B, Shah R.
    Interact Cardiovasc Thorac Surg; 2012 Aug 01; 15(2):258-65. PubMed ID: 22581864
    [Abstract] [Full Text] [Related]

  • 4. Radiofrequency ablation of stage IA non-small cell lung cancer in medically inoperable patients: Results from the American College of Surgeons Oncology Group Z4033 (Alliance) trial.
    Dupuy DE, Fernando HC, Hillman S, Ng T, Tan AD, Sharma A, Rilling WS, Hong K, Putnam JB.
    Cancer; 2015 Oct 01; 121(19):3491-8. PubMed ID: 26096694
    [Abstract] [Full Text] [Related]

  • 5. Treatment-Related Toxicity in Patients With Early-Stage Non-Small Cell Lung Cancer and Coexisting Interstitial Lung Disease: A Systematic Review.
    Chen H, Senan S, Nossent EJ, Boldt RG, Warner A, Palma DA, Louie AV.
    Int J Radiat Oncol Biol Phys; 2017 Jul 01; 98(3):622-631. PubMed ID: 28581404
    [Abstract] [Full Text] [Related]

  • 6. Stereotactic body radiation therapy versus surgical resection for stage I non-small cell lung cancer.
    Crabtree TD, Denlinger CE, Meyers BF, El Naqa I, Zoole J, Krupnick AS, Kreisel D, Patterson GA, Bradley JD.
    J Thorac Cardiovasc Surg; 2010 Aug 01; 140(2):377-86. PubMed ID: 20400121
    [Abstract] [Full Text] [Related]

  • 7. Video-assisted thoracoscopic lobectomy is associated with greater recurrence-free survival than stereotactic body radiotherapy for clinical stage I lung cancer.
    Cornwell LD, Echeverria AE, Samuelian J, Mayor J, Casal RF, Bakaeen FG, Omer S, Preventza O, Mai W, Chen G, Simpson KH, Moghanaki D, Zhu AW.
    J Thorac Cardiovasc Surg; 2018 Jan 01; 155(1):395-402. PubMed ID: 28888379
    [Abstract] [Full Text] [Related]

  • 8. Cost-effectiveness analysis of stereotactic body radiotherapy and radiofrequency ablation for medically inoperable, early-stage non-small cell lung cancer.
    Sher DJ, Wee JO, Punglia RS.
    Int J Radiat Oncol Biol Phys; 2011 Dec 01; 81(5):e767-74. PubMed ID: 21300476
    [Abstract] [Full Text] [Related]

  • 9. Radiofrequency ablation of stage IA non-small cell lung cancer in patients ineligible for surgery: results of a prospective multicenter phase II trial.
    Palussière J, Chomy F, Savina M, Deschamps F, Gaubert JY, Renault A, Bonnefoy O, Laurent F, Meunier C, Bellera C, Mathoulin-Pelissier S, de Baere T.
    J Cardiothorac Surg; 2018 Aug 24; 13(1):91. PubMed ID: 30143031
    [Abstract] [Full Text] [Related]

  • 10. Treatment of stage I lung cancer in high-risk and inoperable patients: comparison of prospective clinical trials using stereotactic body radiotherapy (RTOG 0236), sublobar resection (ACOSOG Z4032), and radiofrequency ablation (ACOSOG Z4033).
    Crabtree T, Puri V, Timmerman R, Fernando H, Bradley J, Decker PA, Paulus R, Putnum JB, Dupuy DE, Meyers B.
    J Thorac Cardiovasc Surg; 2013 Mar 24; 145(3):692-9. PubMed ID: 23174176
    [Abstract] [Full Text] [Related]

  • 11. Wedge resection and radiofrequency ablation for stage I nonsmall cell lung cancer.
    Ambrogi MC, Fanucchi O, Dini P, Melfi F, Davini F, Lucchi M, Massimetti G, Mussi A.
    Eur Respir J; 2015 Apr 24; 45(4):1089-97. PubMed ID: 25700387
    [Abstract] [Full Text] [Related]

  • 12. Cost-effectiveness of Stereotactic Body Radiation Therapy versus Radiofrequency Ablation for Hepatocellular Carcinoma: A Markov Modeling Study.
    Pollom EL, Lee K, Durkee BY, Grade M, Mokhtari DA, Wahl DR, Feng M, Kothary N, Koong AC, Owens DK, Goldhaber-Fiebert J, Chang DT.
    Radiology; 2017 May 24; 283(2):460-468. PubMed ID: 28045603
    [Abstract] [Full Text] [Related]

  • 13. Charlson Comorbidity Index predicts patient outcome, in cases of inoperable non-small cell lung cancer treated with radiofrequency ablation.
    Simon TG, Beland MD, Machan JT, Dipetrillo T, Dupuy DE.
    Eur J Radiol; 2012 Dec 24; 81(12):4167-72. PubMed ID: 22835876
    [Abstract] [Full Text] [Related]

  • 14. Stereotactic Ablative Body Radiotherapy Versus Radical Radiotherapy: Comparing Real-World Outcomes in Stage I Lung Cancer.
    Phillips I, Sandhu S, Lüchtenborg M, Harden S.
    Clin Oncol (R Coll Radiol); 2019 Oct 24; 31(10):681-687. PubMed ID: 31377081
    [Abstract] [Full Text] [Related]

  • 15. Comparison of survival rate in primary non-small-cell lung cancer among elderly patients treated with radiofrequency ablation, surgery, or chemotherapy.
    Lee H, Jin GY, Han YM, Chung GH, Lee YC, Kwon KS, Lynch D.
    Cardiovasc Intervent Radiol; 2012 Apr 24; 35(2):343-50. PubMed ID: 21626257
    [Abstract] [Full Text] [Related]

  • 16. Survival Outcomes of Treatment with Radiofrequency Ablation, Stereotactic Body Radiotherapy, or Sublobar Resection for Patients with Clinical Stage I Non-Small-Cell Lung Cancer: A Single-Center Evaluation.
    Iguchi T, Hiraki T, Matsui Y, Mitsuhashi T, Katayama N, Katsui K, Soh J, Sakurai J, Gobara H, Toyooka S, Kanazawa S.
    J Vasc Interv Radiol; 2020 Jul 24; 31(7):1044-1051. PubMed ID: 32471699
    [Abstract] [Full Text] [Related]

  • 17. Treatment of stage I and II non-small cell lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines.
    Howington JA, Blum MG, Chang AC, Balekian AA, Murthy SC.
    Chest; 2013 May 24; 143(5 Suppl):e278S-e313S. PubMed ID: 23649443
    [Abstract] [Full Text] [Related]

  • 18. A national analysis of wedge resection versus stereotactic body radiation therapy for stage IA non-small cell lung cancer.
    Yerokun BA, Yang CJ, Gulack BC, Li X, Mulvihill MS, Gu L, Wang X, Harpole DH, D'Amico TA, Berry MF, Hartwig MG.
    J Thorac Cardiovasc Surg; 2017 Aug 24; 154(2):675-686.e4. PubMed ID: 28461054
    [Abstract] [Full Text] [Related]

  • 19. Stereotactic body radiation therapy and thermal ablation for treatment of NSCLC: A systematic literature review and meta-analysis.
    Laeseke P, Ng C, Ferko N, Naghi A, Wright GWJ, Zhang Y, Laidlaw A, Kalsekar I, Laxmanan B, Ghosh SK, Zhou M, Szapary P, Pritchett M.
    Lung Cancer; 2023 Aug 24; 182():107259. PubMed ID: 37321074
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.